Neuralstem, Inc., a Maryland based biotech company, announced that the FDA has approved its application to conduct a Phase I safety trial of its stem-cell based approach to treat ALS. This makes Neuralstem the first company approved to conduct a Phase I stem-cell trial for ALS and one of only a small handful of companies approved to test stem-cell based therapies. The ALS non-profit organization, Prize4Life, congratulated Neuralstem for its impressive work and also congratulated Israel-based biotech company, BrainStorm Cell Therapeutics, for its recently-secured funding to complete pre-clinical stem cell trials for ALS. A competitorfor Prize4Life’s Avi Kremer ALS Treatment Prize, BrainStorm expects to begin Phase I ALS clinical trials in early 2010.
Click here to read more.Share this: